Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive Abeta immunotherapy.
Cerebral amyloid angiopathy (CAA) is a common feature of Alzheimer's disease (AD). More advanced stages are accompanied by microhemorrhages and vasculitis. Peripheral blood-borne macrophages are intimately linked to cerebrovascular pathology coincident with AD. Magnetic resonance imaging (MRI) was used to noninvasively study microvascular lesions in amyloid precursor protein transgenic mouse AD models. Foci of signal attenuation were detected in cortical and thalamic brain regions of aged APP23 mice. Their strength and number was considerably enhanced by intravenous administration of iron oxide nanoparticles, which are taken up by macrophages through absorptive endocytosis, 24 h before image acquisition. The number of cortical sites displaying signal attenuation increased with age. Histology at these sites demonstrated the presence of iron-containing macrophages in the vicinity of CAA-affected blood vessels. A fraction of the sites additionally showed thickened vessel walls and vasculitis. Consistent with the visualization of CAA-associated lesions, MRI detected a much smaller number of attenuated signal sites in APP23xPS45 mice, for which a strong presenilin mutation caused a shift toward amyloid β(42), thus reducing vascular amyloid. Similar results were obtained with APP24 and APP51 mice, which develop significantly less CAA and microvascular pathology than APP23. In a longitudinal study, we noninvasively demonstrated the reinforced formation of microvascular pathology during passive amyloid β immunotherapy of APP23 mice. Histology confirmed that foci of signal attenuation reflected an increase in CAA-related lesions. Our data demonstrate that MRI has the sensitivity to noninvasively monitor the development of vascular pathology and its possible enhancement by amyloid β immunotherapy in transgenic mice modeling AD.
Global Imaging Group, Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland. nicolau.beckmann@novartis.com
Nicolau
N
Beckmann
Christelle
C
Gérard
Dorothée
D
Abramowski
Catherine
C
Cannet
Matthias
M
Staufenbiel
D000544:Alzheimer Disease / Q000235:genetics / Q000473:pathology*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000704:Analysis of Variance; D000818:Animals; D016657:Cerebral Amyloid Angiopathy / Q000235:genetics / Q000473:pathology*; D002540:Cerebral Cortex / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D007116:Immunization, Passive; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D018709:Statistics, Nonparametric
D016564:Amyloid beta-Protein Precursor; D058185:Magnetite Nanoparticles
J Neural Transm (Vienna). 2002 May;109(5-6):813-36
12111471
J Neurosci Res. 1996 Nov 01;46(3):283-93
8933367
Science. 2008 Sep 19;321(5896):1686-9
18802001
J Neurosci. 2003 Sep 17;23(24):8453-9
13679413
J Neurochem. 2002 Mar;80(5):799-806
11948243
Brain. 2008 Dec;131(Pt 12):3299-310
18953056
Science. 2002 Nov 15;298(5597):1379
12434053
Nat Neurosci. 2004 Sep;7(9):954-60
15311281
Eur J Clin Invest. 2002 May;32(5):360-71
12027877
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14088-93
10570203
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 May-Jun;1(3):272-98
20049797
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):168-73
20205643
J Neuropathol Exp Neurol. 1997 Mar;56(3):273-84
9056541
J Magn Reson Imaging. 2010 Jan;31(1):142-8
20027582
Acta Neuropathol. 2008 Jun;115(6):599-609
18369648
Annu Rev Neurosci. 2008;31:175-93
18352830
J Neurosci. 2001 Mar 1;21(5):1619-27
11222652
Radiology. 1990 May;175(2):489-93
2326474
AJNR Am J Neuroradiol. 1999 Apr;20(4):637-42
10319975
Invest Radiol. 2003 Jun;38(6):311-9
12908698
Stroke. 1999 Aug;30(8):1637-42
10436114
Neuroscience. 2007 Feb 9;144(3):950-60
17137722
J Pharmacol Exp Ther. 2008 Nov;327(2):411-24
18687920
Neurobiol Aging. 2009 Dec;30(12):1936-48
18359131
Neuron. 2006 Feb 16;49(4):489-502
16476660
Acta Neuropathol. 1998 Mar;95(3):235-44
9542588
Neurology. 2007 Apr 24;68(17):1411-6
17452586
Arch Neurol. 2008 Jun;65(6):790-5
18541799
Stroke. 2004 Nov;35(11 Suppl 1):2616-9
15459438
J Neurosci. 2003 Sep 10;23(23):8231-6
12967984
Magn Reson Imaging. 1995;13(5):675-91
8569442
J Neurosci. 2005 Nov 30;25(48):11125-32
16319312
Mol Med. 1998 Jul;4(7):480-9
9713826
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3587-92
18305170
J Neuroimaging. 2004 Jul;14(3):251-7
15228767
Neurobiol Aging. 2007 Feb;28(2):202-12
16427722
Nat Med. 2007 Apr;13(4):432-8
17351623
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13287-92
9371838
Brain. 2007 Aug;130(Pt 8):1988-2003
17322562